Ann: ATL1102 DMD Clinical Trial Application Submitted in Europe, page-57

Biotech Antisense Therapeutics (ASX:ANP) has submitted its first application for the Phase 2b/3 clinical trial of ATL1102 (its compound) in non-ambulant patients with Duchenne muscular dystrophy (DMD) to the Federal Institute for Drugs and Medical Devices in Germany for their evaluation and subsequent approval.

Morgans expects the first patient to be dosed in 4QCY22 in Europe and sees it as an important milestone as Antisense works with the European regulatory agency to ensure the clinical program, if successful, leads to a regulatory approval.

Antisense is reviewing its cash position, which sits at A$21.7m at 3Q22 to ensure its cash runway is extended for as long as possible. Management note reducing upfront capital requirements and exploring other funding options.

“That’s a positive step forward for Antisense as they also look to extend their cash runway to make their cash last as long as possible

The above is copied and pasted from stock head